QuidelOrtho (QDEL) to Release Earnings on Tuesday

QuidelOrtho (NASDAQ:QDEL) is anticipated to announce its earnings results after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of $1.07 per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.55. The firm had revenue of $727.00 million during the quarter, compared to analysts’ expectations of $642.16 million. QuidelOrtho had a positive return on equity of 4.24% and a negative net margin of 66.25%. The company’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same period last year, the business posted $0.90 earnings per share. On average, analysts expect QuidelOrtho to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

QuidelOrtho Price Performance

Shares of NASDAQ QDEL opened at $42.89 on Monday. QuidelOrtho has a 52 week low of $29.74 and a 52 week high of $69.83. The business’s 50 day moving average price is $43.21 and its 200 day moving average price is $42.29. The company has a quick ratio of 0.81, a current ratio of 1.38 and a debt-to-equity ratio of 0.68. The firm has a market cap of $2.88 billion, a P/E ratio of -1.54 and a beta of 0.08.

Wall Street Analysts Forecast Growth

QDEL has been the subject of several recent research reports. William Blair reissued a “market perform” rating on shares of QuidelOrtho in a report on Wednesday, November 20th. Jefferies Financial Group began coverage on QuidelOrtho in a research note on Tuesday, December 10th. They set a “hold” rating and a $43.00 price objective for the company. StockNews.com upgraded QuidelOrtho from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Citigroup raised QuidelOrtho from a “neutral” rating to a “buy” rating and raised their target price for the stock from $44.00 to $50.00 in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, QuidelOrtho presently has an average rating of “Hold” and an average target price of $53.43.

Insider Transactions at QuidelOrtho

In other news, major shareholder Carlyle Group Inc. sold 8,260,183 shares of QuidelOrtho stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $35.31, for a total value of $291,667,061.73. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Brian J. Blaser purchased 6,033 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were purchased at an average price of $41.42 per share, with a total value of $249,886.86. Following the completion of the transaction, the chief executive officer now directly owns 6,033 shares of the company’s stock, valued at $249,886.86. This represents a ? increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.00% of the company’s stock.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.